Compare Cytokinetics Inc (CYTK) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MSCI Indonesia ETF — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while iShares MSCI Indonesia ETF trades at $12.47. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | EIDO | |
|---|---|---|
Market Cap | $10.78B | — |
Sector | Technology | — |
52-Week High | $87.26 | $19.22 |
52-Week Low | $33.23 | $10.80 |
Enterprise Value | $10.88B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
EIDO, the iShares MSCI Indonesia ETF, trades at $12.91, up 2.38% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows support and resistance clustered around $13. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs and reforestation plans, while facing challenges from foreign capital outflows and central bank rate hikes to support the rupiah.
The outlook for EIDO is mixed, with low valuation offering potential upside, but weak price action and high financial sector exposure limit gains. Risks include geopolitical volatility and dependence on commodity markets, though government reforms could boost long-term growth. Investors should weigh bargain valuations against macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
